Lilly Reports Results of Phase 3 Soft Tissue Sarcoma

Today, Eli Lilly reported that the results of their Phase 3 study of olaratumab (LARTRUVO®) in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma showed no difference in survival between the study arms.

MEET THE PEOPLE OF SARC

Denise Reinke, President and CEO of SARC

Denise Reinke has been with SARC since its inception in 2002 assuming increasing responsibilities over the years. She is uniquely positioned to lead SARC as President and CEO given her sarcoma nurse practitioner, clinical trials, pharmaceutical and business experience.